NVIC Vaccine News

ACIP Votes Against Universal Use of Meningococcal B Vaccines

By Theresa Wrangham, NVIC Executive Director
Published July 12, 2015 in Infectious Diseases & Vaccines


The Centers for Disease Control’s (CDC) Advisory Committee on Immunization Practices (ACIP) met on June 24 and voted against universal recommendations for MenB vaccines. These vaccines were recently approved by the U.S. Food & Drug Administration (FDA) for use in adolescents and young adults.

Considerations used by the ACIP when making universal (Category A) recommendations for vaccines include disease incidence, and benefit for large numbers of children and adults. If the vaccine under consideration doesn’t benefit large numbers of people, it may not be universally recommended.1

Data presented during the meeting showed that a universal recommendation was not justified or cost effective. ACIP instead voted for a Category B recommendation, which means that the vaccine is available for use by doctors and upon patient request. The committee’s decision eliminates financial inequities and access via provisions in the Affordable Care Act (ACA) and Vaccines for Children (VFC) programs.

Serogroup B Incidence Low in U.S.

Invasive meningococcal disease is a bacterial infection that causes inflammation of the meninges of the brain and can lead to a serious blood infection. According to the CDC, humans are the only natural reservoir for invasive meningococcal disease (N. meningitides).2

Serogroup B Incidence Low in U.S.Infection with invasive meningococcal disease requires that an individual must have a susceptibility to the disease and regular close personal contact, such as sharing a toothbrush with or kissing person, who is colonizing meningococcal organisms.

The CDC reports incidence of invasive meningococcal disease in the U.S. as rare, and cases range from 800-1,200 annually, with about one-third of disease incidence being attributed to serogroup B. About half, or 100-200 cases, of serogroup B meningococcal disease in the U.S. occurs in infants too young to receive MenB vaccines.3 4 5

During the meeting, the CDC’s presentation6 noted that incidence for all meningococcal serogroups in the U.S. is at historic lows and continues to decline despite lower than desired vaccine uptake, meaning decline in serogroup B cases cannot be attributed to vaccine.  

Community Immunity to Meningococcal Disease Exists

Natural community immunity also contributes greatly to low disease incidence. Research shows that about 20 to 40 percent of Americans are asymptomatically colonizing meningococcal organisms in their nasal passages and throats.7 8 This colonization boosts individual innate immunity to invasive meningococcal infection throughout life. Infants are protected for the first few months of life by the transfer of maternal antibodies from immune mothers until they can make their own antibodies.9

The CDC has recognized high levels of innate community immunity and noted that the majority of America’s 320 million citizens10 will experience asymptomatic infection as children or young adults without complications and develop bactericidal antibodies against meningococcal disease that protect them.11 12

Even though invasive meningococcal disease is rare, there is a small minority of individuals who are unable to develop antibodies who are at higher risk for this disease.

Safety Concerns Expressed by ACIP Members

During the discussion of MenB vaccines, committee members Kemp and Belongi expressed concern relating to reports of adverse events related to rheumatoid arthritis, thyroiditis and anaphylaxis. Other committee members expressed similar concerns and Chairman Temte noted that safety had been ruled on by the FDA in their licensure of the vaccine. It is unclear if additional data will be provided in response to these concerns.

Universal Recommendation Expensive and Not Justified

Universal Recommendation Expensive and Not JustifiedA CDC cost effectiveness analyses published in 2000 revealed that universal use of meningococcal vaccines in college freshmen students would be very expensive and unlikely to be cost-effective.13 Of the 2.4 million college freshmen in the U.S., vaccinating those living in dormitories would require approximately 300,000-500,000 doses of vaccine to be administered annually. This effort would prevent 15 to 30 cases of invasive disease and one to three deaths. The associated costs were $600,000--$1.8 million to prevent one case of disease, and $7 million to $20 million to prevent one death.14 Vaccination of all college freshmen would require 1.4 – 2.3 million doses annually, and prevent 37-69 cases of disease and two to four deaths at an annual cost of $22 - $48 million.

Although this CDC report was issued prior to the licensure of MenB vaccines in the U.S., cost-effectiveness data presented during the ACIP meeting confirmed that a universal recommendation of MenB would not be cost effective.15

Consequences of Universal Vaccine Recommendations

In 2011 the CDC held a public engagement and stakeholder meeting to obtain feedback the use of meningococcal vaccines given its low incidence. The resulting stakeholder report noted choice, freedom and recommendations versus vaccine requirements and mandates as a unifying theme.16

The report also recognized that universal use recommendations previously made by the ACIP have had have far reaching consequences and have often translated into a vaccine mandate in state school attendance laws.17 The ACIP acknowledged vaccine mandates as a consequence of a universal use recommendations in their voting deliberations.

Risk in All Choices

During the public engagement process and recent ACIP meetings, many families shared their stories of suffering and loss due to invasive meningococcal disease. These stories are not unlike the stories of loss and grief we hear at NVIC about vaccine injury and death.

Risk: Two Sides One CoinThe ACIP was gracious with time given to these families to share their stories and requests for universal recommendation. Chairman Temte also read NVIC’s statement against a universal recommendation.

In our statement we noted that many of these families were also denied their informed consent rights. Their doctors had not told them that a meningococcal vaccine was available to them and while vaccines are not 100% safe or effective for everyone, these families had a right to have access to and make informed choices about meningococcal vaccines for their children.18

Act to Protect Your Rights

These stories also represent a larger universal truth; there is no risk free option, just the ability to decide what risk is acceptable to you when considering a medical treatment/procedure or pharmaceutical product offered by a health care provider. The public debate in legislatures today is who gets to flip that coin and make that risk decision; government or parents and adults?

NVIC tracked, monitored and analyzed over 100 pieces of vaccine related legislation across 36 states this year. Is your state next?

Protect your rights by registering for NVIC’s Advocacy Portal. NVIC provides this tool as a free public resource to empower citizens to protect their human and informed consent right to make vaccine choices free from coercion and discrimination. Once you register you will receive action alerts on legislation supporting or restricting vaccine exemptions in your state, and can access the portal and stay current with legislative up-dates, talking points, and contact your legislators with your concerns with ease. Don’t wait for someone else to protect your rights…that someone is you and your voice makes a difference!



2 Centers for Disease Control. Manual for Surveillance of VPD: Chapter 8: Meningococcal Disease. CDC updated Apr. 1, 2014.
3 Ibid.
4 U.S. Food and Drug Administration. Meningococcal Group B Vaccine. Trumemba product insert.
5 U.S. Food and Drug Administration. Meningococcal Group B Vaccine. Bexsero product insert.
6 ACIP Meningococcal Workgroup Presentation to ACIP. Considerations for routine use of MenB vaccines in adolescents. Jun. 24, 2015.
7 Tan L KK, Cadone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. NEJM April 22, 2010; 362(16): 1511-1520.
10 U.S. Census Bureau. U.S. & World Population Clock.
11 Ibid footnote 2.
13 Centers for Disease Control. Meningococcal Disease and College Students: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. 49(RR07;11-20). Jun. 30, 2000.
14 Ibid endnote 13.
15 Ibid endnote 6.
16 Centers for Disease Control. Engagement Project Report: Meningococcal Vaccines and Infants/Toddlers. Executive Summary. Summer 2011.
17 National Conference of State Legislatures (NCSL). Meningitis Laws at a Glance. NCSL updated 2012.

Leave a comment

Your email address will not be published. Required fields are marked with an *

Name is a required field
Please enter a valid email address
Please enter a comment.
6 Responses to "ACIP Votes Against Universal Use of Meningococcal B Vaccines"
Commenter Name
Deana LaFontaine
Posted: 7/15/2015 10:16:38 AM
Concerning this article. I live in MI and I have a son going into the 7th grade. I do not want him to get this vaccination but it is recommended they he does before entering the 7th grade. I now have to meet with my health department to exempt out of this vaccination before he can attend public school. Why is this if the ACIP is classifying as a Category B? Thank you for your help. Deana LaFontaine Editors note: Vaccine laws are currently State Laws and vary. Here are Michigan's: http://www.nvic.org/Vaccine-Laws/state-vaccine-requirements/michigan.aspx
Commenter Name
Posted: 7/15/2015 11:23:36 AM
I contracted this disease from our au pair who by the way I never kissed. She may used my toothbrush LOL. She was in close contact with my family when sick with a sinus infection with fever. She ate and drank in my home, used our bathroom and kitchen and I cleaned up after her including emptying waste baskets full of soiled tissues. Within days of exposure I was in ICU. This vaccine should used in high risk groups and it should required by law for service industry people. I am completely well but this is a deadly disease. She by the was diagnosed with TB six months after I fired her.
Commenter Name
Posted: 7/15/2015 1:42:05 PM
not so much the safety that may have been the persuading factor in not accepting Meningococcal B Vaccines to be pushed on the masses BUT because of the COSTS involved...
Commenter Name
Posted: 7/15/2015 5:40:20 PM
My son has IGA Nepropathy after he received the Meningococccal B vaccine, I found this based on research I did after he was diagnosed.
Commenter Name
Posted: 7/16/2015 2:37:11 PM
My daughter is going to start 6th grade. This vaccine is a mandatory in NJ for children to start school. My question is about safety. Dont care much about cost. Is this vaccine safe? I am leading against it. Our children already receive too many vaccines. As a child I didn't receive even small percentage what children are getting now.
Commenter Name
Posted: 11/26/2015 12:43:50 AM
Kris, no vaccine is safe or effective. The antibodies are temporary. Wat h dr. Tenpennies video re: What the CDC documents say about vaccines....something to that effect. They admit they cannot show, prove efficacy. Buy dr. Suzannes book "Dissolving Illusions - Disease, Vaccines and the Forgotten History" good luck.
Make A Difference

NVIC is 100% funded by donations.

Connect with Us!

Ask 8 Information Kiosk

Explore FREE downloadable educational materials

NVIC Websites:
Opens in new tab, window
Opens an external site
Opens an external site in new tab, window